Flu season is upon us again with influenza now present in 48 states. So far, the disease has been only sporadically reported, although commercials for the anti-flu drug Tamiflu are already airing in epidemic proportions—not surprising considering that Roche has earned more than $18 billion off the drug since its introduction in 1999. As one financial analyst put it, Tamiflu is “a nice little earner.” I’ll say. But does it work? Continue reading →